Company news
ProQR Therapeutics N.V. news in 2021
ProQR Therapeutics N.V.'s news releases, calls and decks from 2021, newest first.
ProQR Announces Amendment to Convertible Debt Financing Agreement with Pontifax Ventures and Kreos Capital
December 29, 2021
ProQR Announces First Patients Dosed in Phase 2/3 Pivotal Trials of QR-421a for USH2A Mediated Retinitis Pigmentosa
December 15, 2021
ProQR Announces Upcoming Investor Conferences in November and December
November 7, 2021
ProQR Announces Third Quarter 2021 Operating and Financial Results
November 3, 2021
ProQR Appoints Theresa Heggie as Chief Commercial Officer
October 3, 2021
ProQR Announces Conference Call to Discuss the Axiomer® RNA Editing Platform
September 7, 2021
ProQR Announces Axiomer® RNA Editing Licensing and Research Collaboration with Lilly
September 7, 2021
ProQR Announces Virtual Presentation at EURETINA 2021
September 5, 2021
ProQR Announces Second Quarter 2021 Operating and Financial Results
August 4, 2021
ProQR Announces First Quarter 2021 Operating and Financial Results
May 5, 2021
ProQR Therapeutics and Yarrow Biotechnology, an RTW Investments, LP Incubated Company, Announce Exclusive Worldwide License and Discovery Collaboration for Undisclosed Target
May 3, 2021
ProQR Announces Annual Meeting of Shareholders
April 19, 2021
ProQR Announces Publication in Nature Medicine for Sepofarsen in Leber Congenital Amaurosis 10
April 12, 2021
ProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares
April 4, 2021
ProQR Prices $90 Million Underwritten Public Offering of Ordinary Shares
March 29, 2021
ProQR Announces Positive Results from Clinical Trial of QR-421a in Usher Syndrome and Plans to Start Pivotal Trials
March 23, 2021
ProQR Announces Fourth Quarter and Full Year 2020 Operating and Financial Results
February 24, 2021
ProQR Completes Enrollment of its Pivotal Trial of Sepofarsen for the Treatment of LCA10
January 6, 2021
Decks in 2021
- Investor Day (November 2021)
Investor day · 96 slides · Nov 18, 2021
- Investor Presentation (September 2021)
Investor deck · 29 slides · Sep 9, 2021
- Technical Presentation (March 2021)
Technical · 41 slides · Mar 24, 2021